NutriBand Inc.
For the period ended Jan 31, 2025. Filed Apr 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 28, 2025
NTRB$5.76-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
ITEM 16 Exhibits.
| Exhibit | |
|---|---|
| Number | Description |
| 1.1 | [Reserved] |
| 3.1A | Articles of Incorporation.(1) |
| 3.1B | Amendment to Articles of Incorporation, filed May 12, 2016.(1) |
| 3.1 | Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020). |
| 3.1C | Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022.(13) |
| 3.2 | By-laws(1) |
| 3.2B | Amended and Restated By-Laws adopted January 21, 2022.(12) |
| 4.3 | Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC(6) |
| 4.4 | Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 (6) |
| 4.10 | Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC(6) |
| 4.14† | 2021 Employee Stock Option Plan.(11) |
| 4.15† | Form of Stock Option Grant Notice.(11) |
| 4.16 | Form of Common Stock Purchase Warrant issued in the Company’s initial public offering in 2021(9) |
| 4.17 | Form of Warrant issued to the Representative.(14) |
| 4.18† | 2024 Amended and Restated Stock Option Plan, adopted March 20, 2024.(15) |
| 4.19 | Form of Common Stock Purchase Warrant issued in 2024 Equity Financing (18) |
| 5.1 | [Reserved] |
| 10.1 | Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee(1) |
| 10.4 | Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC.(3) |
| 10.5† | Form of agreement with independent directors.(4) |
| 10.6 | Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc.(4) |
| 10.15† | Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.(5) |
| 10.16† | Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.(5) |
| 10.17† | Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.(5) |
| 10.18† | Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.(5) |
| 10.19 | Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC.(7) |
| 10.20 | Security Agreement, between the Company and Pocono Coated Products, LLC.(7) |
| 10.21 | Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.(7) |
| 10.22 | License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.(8) |
| 10.23 | Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.(8) |
| 10.24 | Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.(8) |
| 10.25 | Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC(8a) |
| 10.26 | Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics Corporation.(10) |
| 10.27† | Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan.(12) |
| 10.28† | Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik.(12) |
| 10.29† | Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman.(12) |
| 10.30 | Creditline Promissory Note, dated July 13, 2023. (16) |
| 10.31 | Conversion Agreement, dated December 19, 2023.(17) |
| 10.32 | Form of Subscription Agreement for April 19, 2024 Equity Financing (19) |
| 10.33 | Form of Note Conversion Agreement dated May 13, 202420 |
| 10.35 | Commercial Development and Clinical Supply Agreement (“Agreement”), made on January 4, 2023, between Kindeva Drug Delivery, L.P. and 4P Therapeutics, LLC.* |
| 10.36 | Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC*. |
| 21.1 | List of Subsidiaries of Nutriband Inc.(14) |
| 23.1 | [Reserved] |
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.* |
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.* |
| 32.1 | Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley.* |
| 32.2 | Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley.* |
| 101.INS | Inline XBRL Instance Document.* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| 107 | Filing Fee Table |
| * | Filed herewith. |
| † | Executive compensation plan or arrangement. |
| (1) | Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference. |
| (2) | Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference. |
| (3) | Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference. |
| (4) | Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference. |
| (5) | Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference. |
| (6) | Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference. |
| (7) | Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference. |
| (8) | Filed as exhibits to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference. |
| (8a) | Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference. |
| (9) | Filed as Exhibit 4.12 to Amendment 2 to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021. |
| (10) | Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference. |
| (11) | Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference. |
| (12) | Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference. |
| (13) | Filed as Exhibit 3.1C to the Company’s Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference. |
| (14) | Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference |
| (15) | Filed as Exhibit 4.16 to the Company’s Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference. |
| (16) | Filed as Exhibit 10.30 to the Company’s Current Report on Form 8-K, which was filed with the Commission on July 14, 2023. |
| (17) | Filed as Exhibit No. 10.31 to the Company’s Current Report on Form 8-K, which was filed with the Commission on December 29, 2023. |
| (18) | Filed as Exhibit No. 4.19 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024. |
| (19) | Filed as Exhibit No. 10.32 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024. |
| (20) | Filed as Exhibit No. 10.33 to the Company’s Current Report on Form 8-K, which was filed with the Commission on May 21, 2024. |
(b) Financial Statement Schedules
All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.